# Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

> **NCT00304096** · PHASE1 · COMPLETED · sponsor: **University of Virginia** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine

## Key facts

- **NCT ID:** NCT00304096
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-06
- **Final completion:** 2008-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304096, "Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00304096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*